deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02128841

Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. (CATHAR)

This is a Prospective, Open-label Phase 2 Pilot Study With Independent Evaluation of All Outcomes and a Historical Control Group to Determine if Rivaroxaban (Xarelto) is Feasible and Safe for Prevention of Major Complications in Patients Undergoing a Mechanical Aortic Heart Valve Replacement.

Sponsor: Insel Gruppe AG, University Hospital Bern

Conditions Anticoagulants Aortic Valve Disease Heart Valve Prosthesis Implantation
Interventions Rivaroxaban
Updated 7 times since 2017 Last updated: Nov 15, 2017 Started: Sep 30, 2012 Primary completion: Sep 30, 2017 Completion: Sep 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

not enough patients

Other terminated trials from Insel Gruppe AG, University Hospital Bern

See all terminations from Insel Gruppe AG, University Hospital Bern

Other Anticoagulants trials with similar outcome

Browse all Anticoagulants trials

Listed as NCT02128841, this PHASE2 trial focuses on Anticoagulants and Aortic Valve Disease and remains terminated or withdrawn. Sponsored by Insel Gruppe AG, University Hospital Bern, it has been updated 7 times since 2012, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Dec 2017 · 11 months · monthly snapshotSuspended~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2023 · 30 months · monthly snapshotTerminated~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2023 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Dec 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Suspended → Terminated

  2. Jan 2017 — Dec 2017 [monthly]

    Suspended PHASE2

    First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Insel Gruppe AG, University Hospital Bern
Data source: Insel Gruppe AG, University Hospital Bern

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations